Delays or Risks Loom as TrivarX Prepares Stabl-Im Phase 1 Trial
TrivarX has contracted Beyond Drug Development to drive its Stabl-Im MRI imaging platform into Phase 1 trials, aiming to start safety testing in healthy volunteers by late 2026.
- Beyond Drug Development appointed for Phase 1 trial
- Stabl-Im uses stable isotopes for tumour imaging
- Phase 1 focuses on safety in healthy volunteers
- Trial start targeted for second half of 2026
- Step toward Phase 2 efficacy and commercialisation
Specialist CRO Onboard for Phase 1 Safety Trial
TrivarX Limited (ASX:TRI) has taken a significant step forward in the clinical development of its Stabl-Im imaging technology by engaging Beyond Drug Development, a boutique Contract Research Organisation (CRO) with deep expertise in early-phase clinical trials. This partnership is aimed at advancing the planned Phase 1 safety trial, which is set to commence in the second half of calendar year 2026.
Stabl-Im is a proprietary MRI-based functional imaging platform that visualises actively replicating tumour cells using stable isotope tracers rather than radioactive substances. This approach promises a safer and more accessible alternative to traditional oncology imaging, leveraging existing MRI infrastructure to provide earlier and more biologically relevant insights into tumour activity and treatment response.
Trial Design and Initial Focus Areas
The Phase 1 study will be an open-label, sequential-cohort trial assessing safety and tolerability in healthy volunteers following oral dosing of Stabl-Im. Beyond’s initial role includes finalising the clinical protocol, preparing regulatory and clinical documentation, and selecting suitable clinical sites. This groundwork is critical to ensure the trial meets regulatory standards and is positioned for successful execution.
Beyond Drug Development’s team averages over 20 years of experience, including specialist regulatory toxicology expertise exceeding 30 years, which is expected to strengthen TrivarX’s clinical and regulatory strategy. This engagement marks a key milestone in TrivarX’s broader plan to progress Stabl-Im towards Phase 2 efficacy studies and eventual commercial applications in oncology imaging.
Leadership Confidence and Strategic Direction
Incoming CEO Dr Danielle Meyrick, who brings more than two decades of experience in radiopharmaceuticals and clinical development, emphasised the importance of this collaboration. Having previously worked with Beyond, she highlighted their relevant expertise in early-phase development and imaging product advancement as a strong asset as the company prepares for the Phase 1 trial start.
Dr Meyrick described Stabl-Im as a "highly differentiated imaging platform" with potential applications beyond oncology, offering early and clinically meaningful insights into tumour biology through a stable isotope tracer. The upcoming Phase 1 safety data will be pivotal in supporting future efficacy trials and commercialisation efforts.
This development follows TrivarX’s recent new CEO appointment and Phase 1 progress and builds on earlier funding rounds that have underpinned the clinical and regulatory groundwork for Stabl-Im’s advancement $3.5M second-tranche funding.
Bottom Line?
Beyond Drug Development’s engagement signals TrivarX’s commitment to rigorous clinical validation of Stabl-Im, with Phase 1 safety data set to unlock the next stage of oncology imaging trials.
Questions in the middle?
- How will Phase 1 safety data influence regulatory pathways for Stabl-Im?
- What are the potential timelines and hurdles for transitioning to Phase 2 efficacy studies?
- Could Stabl-Im’s stable isotope imaging platform extend beyond oncology into other clinical areas?
